What is Basaglar Cartridge?
Basaglar cartridge is an insulin glargine manufactured by Cipa Ltd. Basaglar cartridge is made by recombinant DNA technology with a non-pathogenic laboratory strain of escherichia coli and differs from human insulin by the replacement of aspargine at the A21 position of A-chain with glycine and addition of two arginines to B31 and B32 of the B-chain.
Basaglar cartridge contains 100 units/mL.
What Is It Used For?
Basaglar cartridge is a long-acting insulin used to lower blood glucose levels in patients with type 1 and type 2 diabetes. It can be used with prandial insulin preparations and non-insulin anti-diabetic agents.
How Does It Work?
The duration of action of the Basaglar cartridge is up to 24 hours and can be used for once-daily dosing. Insulin glargine is called “basal insulin” as it gives low concentrations of insulin and can keep blood sugar stable between meals. It is given with short-acting insulin or “bolus insulin” like insulin lispro, insulin glulisine, and insulin aspart to provide higher doses of insulin.
How to Take It?
Basaglar cartridge should be inserted in a Basaglar KwikPen. This medicine should be injected 15 minutes before meals or 20 minutes after meals. Pull a skin in the abdomen, thighs, or upper arms, then administer the drug subcutaneously and make sure not to inject it in muscles or veins. Wait for 6 seconds before pulling the needle from the site of injection. Always rotate the administration site to avoid skin irritation.
The doctor will determine the correct dose for each patient who will be using the Basaglar cartridge. The doctor will base this on the patient’s blood sugar tests and lifestyle. Do not take a double dose of insulin glargine.
Common side effects of the Basaglar cartridge are low blood sugar, headache, dizziness, anxiety, nervousness, skin rashes, and pain or swelling at the injection site.
Warnings, Precautions, and Contraindications
Blood sugar monitoring if the patient is having hypoglycaemic attacks or will develop allergic reactions to the ingredients of the Basaglar cartridge. It is unsafe to use this medication with alcohol and dose adjustment should be applied if the patient has renal or hepatic problems. The administration should not be used intramuscularly, intravenously, or in insulin pump administration.
Basaglar cartridges may cause hypokalemia, hypoglycemia, amyloidosis at the site of injection, and the development of insulin antibodies. It can rarely affect visual impairment or will cause retinopathy and cataract. Lipohyperthrophy, lipoatrophy, and rare edema can occur at the site of administration of this drug. Severe or prolonged hypoglycemic episodes and allergic reactions can be potentially fatal to the patient.
The unopened cartridge of Basaglar should keep away from direct heat and stored in a refrigerator between 36-46°F (2-8°C) but do not freeze. Opened Basaglar cartridges must be stored at room temperature <86°F (<30°C) for up to 28 days after the first use. Opened cartridges in use must never be removed or reinserted in the Basaglar KwikPen.